Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Med Princ Pract ; 20(1): 85-9, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21160221

RESUMO

OBJECTIVE: To review the target levels of calcium (Ca), phosphate (P), calcium phosphate products (Ca × P) and intact parathyroid hormone (iPTH) levels in patients undergoing hemodialysis (HD) and peritoneal dialysis (PD) and compare them with the Kidney Disease Outcome Quality Initiative (K/DOQI) recommendations. SUBJECTS AND METHODS: Three hundred and fifty-seven patients who had been undergoing dialysis for more than 3 months were included. Patients who had undergone a parathyroidectomy were excluded. The levels of Ca, P, iPTH and Ca × P were monitored for the last 3 months. The Ca and P levels were measured by standard techniques, and iPTH was assessed by the intact molecule assay. RESULTS: Between HD and PD patients, there was no statistically significant difference for age, duration of dialysis or primary disease causing end-stage renal disease. The percentage of patients whose serum Ca, P, Ca × P product and iPTH were within K/DOQI recommended target ranges were 61.2, 66.4, 82.2 and 28.3% in HD patients, and 56.3, 60.6, 85.9 and 22.5% in PD patients, respectively. When all results for each group - HD and PD - were analyzed, 12.8% of patients had all 4 markers within the target range. CONCLUSION: Achieving target ranges of mineral markers is important in dialysis patients, but reaching K/DOQI target levels is difficult. Hence, physicians should be careful in using P binders and vitamin D analogs to achieve the normal ranges.


Assuntos
Fosfatos de Cálcio/sangue , Cálcio/sangue , Nefropatias/terapia , Hormônio Paratireóideo/sangue , Fosfatos/sangue , Diálise Renal , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Diálise Peritoneal , Valores de Referência , Estudos Retrospectivos , Perfil de Impacto da Doença , Turquia
2.
Transplant Proc ; 51(2): 565-567, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30879591

RESUMO

This is the first case report from Turkey to describe a renal transplant complicated by subcutaneous blastomycosis and BK infection. The cutaneous lesions were successfully treated with amphotericin B and fluconazole. The presence of BK infection led to graft failure. Infections with uncommonly seen organisms should be kept in mind due to the impaired T-cell immunity in transplantation.


Assuntos
Blastomicose/imunologia , Hospedeiro Imunocomprometido , Transplante de Rim/efeitos adversos , Infecções por Polyomavirus/imunologia , Infecções Tumorais por Vírus/imunologia , Anfotericina B/uso terapêutico , Antifúngicos/uso terapêutico , Vírus BK , Blastomicose/tratamento farmacológico , Coinfecção , Fluconazol/uso terapêutico , Humanos , Masculino , Turquia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA